2026 - Introduced
Ohio S.B. 434
  • Establishes the Verified Opioid and Intoxicant Consumer Education (VOICE) Act to require clear, evidence-based education on the risks of opioid, as well as available non-opioid pain management options, before patients begin or continue opioid therapy.
Education
Read Senate Bill
2025 - Introduced
Oklahoma H.B.1416
  • Ensures that a non-opioid drug approved by the FDA is not disadvantaged or discouraged with respect to coverage relative to an opioid for the treatment or management of pain on the state preferred drug list.
State Employee Health Plan Parity
Read Bill
2026 - Introduced
Oklahoma S.B. 1563
  • Requires the state Medicaid program and regulated health plans cover FDA-approved non-opioid pain treatments without requiring patients to try opioids first and without less favorable coverage or higher cost-sharing than opioid treatments.
  • Prohibits Medicaid formularies and carrier utilization controls from disadvantaging clinically appropriate non-opioid pain treatments, such as through prior authorization or step therapy, compared to opioids.
  • Directs the state to leverage grants and opioid settlement funds to support education on non-opioid options.
Medicaid ParityState Regulated Commercial Parity
Read Senate Bill
2024 - Passed
Oklahoma S.B.1344
  • Requires that the state Medicaid preferred drug list and utilization management not disadvantage a non-opioid pain medication relative to an opioid pain medication.
  • Requires the state government to seek grant opportunities relating to education and services regarding non-opioid medications.
  • Provides that the state may assist in using opioid settlement funds to support education regarding non-opioid alternatives.
Medicaid ParityEducation
Read Bill
2025 - Passed
Oregon H.B. 3211
  • Requires the Oregon Health Authority to develop a non-opioid directive form.
Read Bill
2025 - Introduced
Oregon S.B.598
  • Requires health insurers and Medicaid establish parity for opioids and non-opioid treatments.
Medicaid ParityState Regulated Commercial Parity
Read Bill
2026 - Introduced
Pennsylvania H.B. 2060/S.B. 1196
  • Requires Medicaid and commercial insurers to provide pain parity by ensuring FDA-approved non opioid drugs are not disadvantaged in coverage, cost sharing, or utilization controls compared with opioids, applying upon FDA approval.
Medicaid ParityState Employee Health Plan Parity
Read House BillRead Senate Bill
2026 - Introduced
Rhode Island S.B. 3022/H.B. 2060
  • Requires health insurers to provide equal access to FDA-approved non-opioid pain medications, eliminating prior authorization and step therapy requirements that currently give opioids a prescribing advantage.
State Employee Health Plan Parity
Read Senate BillRead House Bill
2025 - Introduced
South Carolina S.B. 161/H.B. 4165
  • Prohibits preferencing coverage of an opioid prescription treatment over a non-opioid treatment and requires the South Carolina Department of Public Health to create educational materials and guidelines for practitioners about non-opioid alternative treatment options.
Medicaid ParityEducation
Read Senate BillRead House Bill
2026 - Introduced
South Dakota H.B. 1085
  • Prohibits South Dakota insurers from denying coverage of a prescribed non-opioid medication in favor of an opioid.
  • Bars insurers from imposing stricter utilization controls or higher cost-sharing for non-opioid drugs than for clinically appropriate opioid or narcotic drugs.
State Regulated Commercial Parity
Read House Bill
2025 - Introduced
South Dakota H.B.1137
  • Ensures FDA-approved non-opioid drugs are not disadvantaged or discouraged with respect to coverage of an opioid on the state preferred drug list.
Medicaid ParityState Regulated Commercial Parity
Read Bill
2026 - Passed
Tennessee H.B. 1741/S.B. 1790
  • Requires a health insurer that offers a policy covering an inmate incarcerated in Tennessee to adopt or amend their preferred drug list so that any FDA-approved non-opioid medication is not disadvantaged or discouraged in coverage compared with an opioid for the treatment or management of pain.
State Regulated Commercial Parity
Read House BillRead Senate Bill